Loading...

STAR Strides Pharma Science Ltd Product Launches Announcement

Strd

STR

Strides Pharma Science Ltd

(STAR)

2023 Announcement

Show Summary

Show Summary

Management Change

Earnings Call Transcript

Compliance Report

Promoter Reclassification

Financial Results Published

Earnings Call Audio

Promoters Reclassification

Secretarial Auditor Appoint...

Strong FY25 Results

Demerger Announcement

Reclassification Request

Earnings Call Scheduled

Management Changes

ANDAs Acquisition

New Subsidiary Formed

Management Changes

Amexel Acquisition

De-merger Announcement

Subsidiary Dissolution

Acquisition of Amexel

Postal Ballot Notice

Earnings Call Update

Financial Results Published

Earnings Call Audio

Office Relocation

Management Changes

Strong Q3FY25 Performance

Earnings Call Scheduled

Onesource Listing

ESG Rating Achieved

Transfer Pricing Order

FDA Approval Received

Cost of Acquisition Guidance

Share Allotment Announcement

Scheme Approval

Share Allotment

Scheme Effective Date

Fundraising Success

Management Change

OneSource Creation

Postal Ballot Notice

Strong Q2 Results

Strong Q2 Performance

Stake Acquisition

Financial Results Update

Earnings Call Recording

Solar Energy Investment

Director Re-appointment

Strong Q2 Performance

Earnings Call Announcement

OneSource Fundraising

Scheme Petition Notice

Sustainability Report Released

Debt Redemption

OneSource Update

RBI Order Received

FDA Approval Received

Amalgamation Completion

OneSource Creation Approval

Partial NCD Redemption

FDA Approval Received

AGM Notice 2024

Management Resignation

Annual Meeting Notice

Promoter Reclassification

FDA Compliance Report

Subsidiary Dissolution

Amalgamation Approval

Investor Conference

Acquisition of Stake

Earnings Call Transcript

Earnings Call Outcome

Directorate Change

Financial Results Publication

Earnings Call Outcome

Reclassification Approval

Allotment of Shares

Strong Q1FY25 Earnings

Acquisition in New Zealand

Re-classification Request

Earnings Call Announcement

Equity Share Transfer to IEPF

Advertisement Publication

Compliance Report Submission

Earnings Call Transcript

Financial Results Publication

Proposal Approval

Earnings Call Audio Recording

Insolvency Disposal

Stock Options Grant

Share Allotment

Management Changes

Financial Performance Update

FDA Approval for Oral Suspe...

USFDA Approval for Sevelame...

Shares Allotment

Compliance Certificate Subm...

Compliance Certificate

USFDA Approval Announcement

Completion of FDA Inspection

Business Model Revision

Acquisition Announcement

Newspaper Advertisement

Corporate Guarantee Approval

Insolvency Petition Against...

Newspaper advertisement

USFDA Approval for Gabapent...

Earnings Call Transcript Re...

Investor Meeting

Divestment of Stake

Financial Results Advertise...

Earnings call recording ann...

Statement of Deviation/ Var...

Allotment of Shares

Corporate Guarantee on beha...

Appointment of Director

Q3FY24 Revenue and EBITDA Y...

Acquisition in Associate Co...

Investment in AMP Energy

Sale of Manufacturing Facility

Update on Stelis Biopharmas...

Credit Facility for Trinity...

Closure of Transaction

Partnership with Amneal

Earnings Call Transcript

Advertisement - Financial R...

Earnings call audio recording

Management Changes

Management Change

Confirmation of no deviatio...

Allotment of shares

Earnings Report

Sale of Manufacturing Facility

Investor Conference Call

US FDA Approval

Scheme of Arrangement

Investor Conference Call

Product Approval

Board Meeting and Investors...

Acquisition Approval

Management Resignation

Corporate Guarantees

Financial Statements

Financial Statements

Investor Meetings

Changes in capital structure

Merger of Equals

Financial Statements

Financial Statements

Equity Offerings

Divestment of Assets

Financial Statements

Related Party Transactions

Equity Offerings

Employee Stock Options

Financial Statements

US FDA Inspection

Equity Offerings

Equity Offerings

Equity offer on a preferent...

External Links:

Data:

Strides Pharma Sciences subsidiary has received tentative USFDA approval for Dolutegravir tablets, expanding its range of HIV treatments and adding a market opportunity of $1,345 million in the US.

AI Assistant

Strides Pharma Science Ltd

2023

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.